“…We should also mention some other biomarkers that could be interesting for further studies, including imaging purposes, like TSPO/PBR (translocator protein (18kDa)) also known as Mitochondrial Benzodiazepine Receptor (peripheral), thus supporting its current role as a putative imaging biomarker for AD [448], [449], [450], [451], [452], [453], [454], [455], C1S (complement component 1, s subcomponent) [456], [457], [458], [459], [460], [461], FDFT1 (the squalene synthase gene), which is critical for cholesterol synthesis [462], [463], BMP4 [92], [96], [464], [465], CD68 (as marker of enhanced lysosomal activity) [450], [466], [467], [468], [469], [470], [471], [472], SERTAD2/TRIP-Br2 [473], [474], [475], LTF (Lactotransferrin) [476], [477], [478], FTL (ferritin, light polypeptide; Ferritin light chain) [479], [480], [481], [482], MTF1 (Metal-regulatory transcription factor 1) [483], [484], [485], GSTA3 (Glutathione S-transferase A3), GSTM4 (Glutathione S-transferase M4), MT1L (Metallothionein 1L (gene/pseudogene) [486] (a human-specific truncated protein which may have changed its function or suppressed it [487]), MT1H (Metallothionein 1H) [488], MT1F (Metallothionein 1F) [488], [489] (Figure 16). These last three upregulated genes need to be put in concert with other reports on methallothioneins in AD brains [490], [491], [492].…”